Loading cancer entity…
Loading cancer entity…
Clinical trials
58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03076554 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07006727 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | recruiting | Phase 1 | 116 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 22, 2026 | clinicaltrials |
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07824505 | Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy | completed | Phase 2 | 74 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | suspended | Phase 1 | 90 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07324629 | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma | recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03463460 | Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | active not recruiting | Phase 2 | 9 | Dwight OwenOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750353 | A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas(XANTHOS) | not yet recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Aug 6, 2026 | clinicaltrials |
| NCT01025089 | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | active not recruiting | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03295227 | Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer | recruiting | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07693855 | Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors(THOR) | not yet recruiting | N/A | 69 | National Taiwan University HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07598955 | Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma(SELECT-NK-THYM) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT03134118 | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)(NIVOTHYM) | active not recruiting | Phase 2 | 55 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 15, 2026 | clinicaltrials |
| NCT06019468 | Neoadjuvant Treatment For Locally Advanced Thymic Cancer | recruiting | Phase 2 | 25 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06402708 | Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) | recruiting | Phase 3 | 172 | Fudan UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06141369 | Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) | recruiting | N/A | 21 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07479628 | Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma | not yet recruiting | Phase 2 | 31 | Shanghai Chest HospitalOTHER | 0 | Mar 18, 2026 | clinicaltrials |
| NCT04710628 | Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents(PECATI) | completed | Phase 2 | 43 | MedSIROTHER | 3 | Feb 19, 2026 | clinicaltrials |
| NCT07328074 | Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis | not yet recruiting | — | 70 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT01385722 | Molecular Analysis of Thoracic Malignancies | enrolling by invitation | — | 1,000 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06838910 | Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03694002 | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 21 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT07179341 | Survival Nomogram for Patients With Thymic Carcinoma | completed | N/A | 156 | Weijie YeOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05667948 | Molecular Analysis and Treatment Options of Thymic Malignancies | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04321330 | A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04925947 | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06301945 | Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors(INTHYM) | recruiting | — | 1,020 | Erasmus Medical CenterOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04469725 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | terminated | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04662645 | Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers | completed | N/A | 68 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT00010257 | Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03449173 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)(Style) | unknown | Phase 2 | 56 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04614818 | A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like Carcinoma | unknown | — | 700 | Sun Yat-sen UniversityOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02364076 | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | unknown | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT00198133 | Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma | completed | Phase 2 | 27 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01364727 | A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies | completed | Phase 2 | 33 | Heather WakeleeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01011439 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | terminated | Phase 2 | 72 | Tiziana Life Sciences LTDINDUSTRY | 3 | Feb 6, 2019 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials